IGFBP2 and Hyperinsulinemia: Hyperinsulinemia reduces hepatic synthesis of IGFBP-1 and IGFBP-2, thereby indirectly enhancing this signaling pathway and activating multiple classical oncogenic pathways, ultimately accelerating breast cancer progression [42].